Key takeaways
- • Trial: Survodutide Phase 2 (obesity) (NCT04667377) — Phase 2, 387 participants over 46 weeks.
- • Drug studied: Survodutide (investigational) (Survodutide (investigational)) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from baseline to week 46
- • Key result: Up to 18.7% mean body-weight reduction at 46 weeks on the highest survodutide dose versus 2.0% on placebo
- • Published: The Lancet Diabetes & Endocrinology, 2024.
Study design
Survodutide Phase 2 (obesity) was a phase 2 randomized controlled trial enrolling 387 participants over 46 weeks. The trial studied Survodutide (investigational) (Survodutide (investigational)) for obesity / overweight and was published in The Lancet Diabetes & Endocrinology in 2024.
Primary endpoint
Percent change in body weight from baseline to week 46
Key results
| Measure | Value |
|---|---|
| Headline result | Up to 18.7% mean body-weight reduction at 46 weeks on the highest survodutide dose versus 2.0% on placebo |
| Mean weight loss (highest dose arm) | 18.7% |
| Participants | 387 |
| Duration | 46 weeks |
| Phase | Phase 2 |
Citation
Survodutide Phase 2 (obesity). Published in The Lancet Diabetes & Endocrinology, 2024.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Survodutide (investigational) drug page — pricing, FDA status, side effects, alternatives
- All survodutide (investigational) trials
- GLP-1 clinical trials database
Important: This trial was conducted on the FDA-approved branded product Survodutide (investigational). Compounded versions of Survodutide (investigational) have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.